Suleyman DOLU, Emre ASİLTÜRK, Yildiz KİLAR SOZER, Melahat COBAN, Bekir EROL, Hamit Yasar ELLİDAG, Ayça İNCİ

The association of fibroblast growth factor 23 with atherosclerosis and arterial stiffness in peritoneal dialysis patients

Aim: Increased serum fibroblast growth factor-23 (FGF-23) levels are associated with adverse cardiovascular events in chronickidney disease patients. The aim of our study was to investigate the association of FGF-23 with atherosclerosis and arterial stiffnessin patients with peritoneal dialysis (PD).Material and Methods: This cross-sectional study was performed in 55 (34 (61.8%) male/21 (38.2%) female) PD patients with amean age of 53.1±11.4 years. The presence of atherosclerosis was determined by carotid artery-intima media thickness (CA-IMT)and the presence of arterial stiffness was determined by brachial-ankle pulse wave velocity (baPWV). Residual renal function wasdetermined by residual glomerular filtration rate (rGFR), renal creatinine clearance (CCr), and residual urine output. FGF-23 andsoluble klotho (s-KL) levels were determined by enzyme-linked immunosorbent assay.Results: CA-IMT (p < 0.001), baPWV (p = 0.003 ), log10 FGF-23 (p < 0.001) were higher and s-KL (p < 0.001) was lower compared withthe healthy controls. rGFR (p= 0.007), residual diuresis (p = 0.004) and renal CCr (p = 0.001) were higher in patients with log10 FGF-23≤ 2.16 than log10 FGF-23 > 2.16. In multiple regression analysis there was an inverse relationship between log10 FGF-23 and rGFR (p =0.032), residual diuresis (p = 0.048), renal CCr (p = 0.045). There was no relationship with log10 FGF-23 and CA-IMT, baPWV (p > 0.05).Conclusion: Increased atherosclerosis and arterial stiffness were detected in PD patients compared to healthy subjects. There wasno relationship between FGF-23 and atherosclerosis and arterial stiffness in PD patients.

PDF

___

1. Prichard S. Major and minor risk factors for cardiovascular disease in peritoneal dialysis. Perit Dial Int 2000;20 S154-9.
2. Attman PO, Samuelsson OG, Moberly J, et al. ApolipoproteinB-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-42.
3. Gao N, Kwan BC, Chow KM, et al. Arterial pulse wave velocity and peritoneal transport characteristics independently predict hospitalization in Chinese peritoneal dialysis patients. Perit Dial Int 2010;30:80-5.
4. Covic A, Goldsmith DJ, Florea L, et al. The influence of dialytic modality on arterial stiffness, pulse wave reflections, and vasomotor function. Perit Dial Int 2004;24:365-72.
5. Szeto CC, Kwan BC, Chow KM, et al. Prognostic value of arterial pulse wave velocity in peritoneal dialysis patients. Am J Nephrol 2012;35:127-33.
6. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:4041-8.
7. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrology Dialysis Transplantation 2005;20:1295–1298.
8. Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 2004;19:1480-8.
9. Balci M, Kirkpantur A, Gulbay M, et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid arteryatherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010;14:425-32.
10. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
11. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in nondiabetic and diabetic hemodialysis patients. Osteoporos Int 2006;17:1506-13.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Canada-USA (CANUSA) peritoneal dialysis study group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996;7:198-207.
14. Van-Olden RW, Krediet RT, Struijk DG, et al. Measurement of residual renal function in patients treated with continuous peritoneal dialysis. J Am Soc Nephrol 1996;7:745-50.
15. Twardowski ZJ, Nolph KO, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1987;7:138-47.
16. Szeto CC, Chow KM, Woo KS, et al. Carotid intima media thickness predicts cardiovascular diseases in Chinese predialysis chronic kidney diseases patients. J Am Soc Nephrol 2007;18:1966-72.
17. Yokoyama H, Shoji T, Kimoto E, et al. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J Atheroscler Thromb 2003;10:253-8.
18. Rossi A, Bonfante L, Giacomini A, et al. Carotid artery lesions in patients with nondiabetic chronic renal failure. Am J Kidney Dis 1996;27:58-66.
19. Avram MM, Fein PA, Antignani A, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989;87:55N-60N.
20. Johansson AC, Samuelsson O, Attman PO, et al. Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Perit Dial Int 2000;20:306-14.
21. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein (a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-20.
22. Wang AY. Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 2007;27:S223-7.
23. Chung AW, Yang HH, Kim JM, Sigrist MK, Brin G, Chum E, Gourlay WA, Levin A. Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: an exploratory study. Nephrol Dial Transplant 2010;25:4031-41.
24. Sipahioglu MH, Kucuk H, Unal A, et al. Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients. Perit Dial Int 2012;32:73–80.
25. Yamashina A, Tomiyama H, Arai T, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003;26:615-22.
26. Asicioglu E, Kahveci A, Arikan H, et al. Fibroblast Growth Factor-23 Levels Are Associated with Vascular Calcifications in Peritoneal Dialysis Patients. Nephron Clin Pract 2013;124:89-93.
27. Zeng Y, Feng S, Han OY, et al. Role of fibroblast growth factor-23 in the pathogenesis of atherosclerosis in peritoneal dialysis patients. Genet Mol Res 2015;14:719-29.
28. Moldovan D, Moldovan I, Rusu C, et al. FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. Int Urol Nephrol 2014;46:121-8.
29. Janda K, Krzanowski M, Chowaniec E, et al. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn 2013;123:149-55.
30. Page DE, Knoll GA, Cheung V. The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients. Adv Perit Dial 2002;18:189-91.
31. Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010;29:137-44.
32. Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 2014;85:1103-11.
33. Yamada S, Tsuruya K, Taniguchi M, et al. Relationship Between Residual Renal Function and Serum Fibroblast Growth Factor 23 in Patients on Peritoneal Dialysis. Ther Apher Dial 2014;18:383-90.
34. Ozdemir FN, Güz G, Sezer S, et al. Atherosclerosis risk is higher in continuous ambulatory peritoneal dialysis patients than in hemodialysis patients. Artif Organs 2001;25:448-52.
35. Ashikaga E, Honda H, Suzuki H, et al. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 2010;14:315-22.